Podcasts about health technology assessment

In the previous episode we heard how some rationally-designed therapies work on almost any cancer with the right molecular signature. Tumour-agnostic medications could be godsend for patients with rare cancers which have classically been overlooked by drug developers, and those with advanced cancers of unknown origin. 15,000 such patients have undergone comprehensive genome profiling of their tumours through the organisation, Omico. In this podcast, Omico's founder explains that while the majority have received recommendations about matched therapies, clinical trials are typically the only way to enable access. Professor David Thomas discusses why Australia's Health Technology Assessment process appears to be so conservative and how the market price of next-generation oncotherapies might be brought down by changes across the local ecosystem. Guest Prof David Thomas FRACP PhD (Director, Centre for Molecular Oncology UNSW; Founder and Chief of Science, Omico)  Professor Thomas or Omico have received grants, consultancies or research support from Roche, Astra Zeneca, Pfizer, Eisai, Illumina, Beigene , Elevation Oncology, RedX Pharmaceuticals, SunPharma , Bayer, George Clinical, Novotech , Merck Sharpe and Dohme, Boehringer Ingelheim, Hummingbird, Microba , BioTessellate , PMV Pharma, Australian Unity and Foundation Medicine. ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes  ‘Multicolor' and ‘Pulse Voyage' by Chill Cole. ‘Impulsing', ‘the City of Hope' ‘Over Again', and ‘Going Undercover' by Borrtex provided courtesy of FreeMusicArchive. Image by Guido Mieth licenced through Getty Images.  Editorial feedback kindly provided by RACP physicians Simeon Wong, Stephen Bacchi. Thanks also to Kym Bramich and Arnika Martus on staff with Omico and RACP respectively.  Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O'Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our expertsThis episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/For support with real-world evidence analysis, health economic modelling of health technology assessment, email info@mtechaccess.co.uk or visit https://mtechaccess.co.uk/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Greetings Glocal Citizens! Over the past few weeks, we've been learning more and more about the Women of Africa Post-Pandemic Empowerment and Advocacy Programme with guests from Egypt to Scotland to Nigeria with a range of business, health and well-being perspectives. This week we're back in Nigeria with the women that started it all, Glocal Citizen, Adebisi Bright (https://glocalcitizens.fireside.fm/guests/adebisi-bright). Dr. Bisi Bright is an international award-winning scientist, social entrepreneur, health systems researcher, adjunct lecturer, consultant clinical pharmacist, and public health manager. She is 1st Vice Chairman and CEO of LiveWell Initiative LWI, a self-sustaining nonprofit healthcare social enterprise, which has impacted over two million Nigerians and thousands of Ghanaians with health literacy, improved overall health, and wellness. She is the brain behind the Post-pandemic Womens' Empowerment Programme of Africa which is a Gilead-Sciences, Inc. USA-supported regional program empowering all women in Africa and visiting ten nations with a goal of empowering all the Women of Africa in the post-pandemic era and to equip them tools for mental health and resilience. When we last spoke with Bisi, it was during the pandemic and we got to know how LWI was doing it's part to equip communities with necessary health supports. In this conversation you'll learn about the impressive strides the Bisi and her colleagues have made in services and in innovation all while continuing to live well! Where to find Bisi and more information about the PPWA program? www.livewellng.org (https://www.livewellng.org) On LinkedIn (https://www.linkedin.com/in/bisi-bright-33a22b23/) What's Bisi cooking? Jollof rice (https://en.wikipedia.org/wiki/Jollof_rice) Ogbono soup (https://allnigerianfoods.com/nigerian-ogbono-soup/) Other topics of interest: Global Public Health University (https://gphuniversity.org) Health Technology Assessment (https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/assessment) About Value-based Healthcare (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185050/) International Alliance of Patient's Organizations (https://www.iapo.org.uk) More about Block Chain technology in healthcare (https://builtin.com/blockchain/blockchain-healthcare-applications-companies#:~:text=Blockchain%20has%20many%20uses%20in,for%20clinical%20research%20and%20development.) Special Guest: Adebisi Bright.

Carin Uyl-de Groot is hoogleraar Health Technology Assessment aan de Erasmus Universiteit in Rotterdam.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners, Johnson & Johnson, en Scribes Tax Lawyers.

EinBlick – nachgefragt Podcast mit Interviews und Diskussionsrunden mit Expert:innen des Gesundheitswesens Deutschland muss besser werden bei der Effizienz im Gesundheitswesen Fachjournalist und EinBlick-Redakteur Christoph Nitz spricht über die Messung der Leistungsfähigkeit des Gesundheitssystems mit Professor Reinhard Busse Reinhard Busse ist seit 2002 Professor für Management im Gesundheitswesen an der Technischen Universität Berlin. Er ist Co-Director des European Observatory on Health Systems and Policies und Fakultätsmitglied der Charité – Universitätsmedizin Berlin. Seine Forschungsschwerpunkte umfassen Gesundheitssystemforschung, Versorgungsforschung, Gesundheitsökonomie und Health Technology Assessment. Professor Busse hat in Marburg, Boston und London Medizin sowie in Hannover Public Health studiert und sich 1999 an der Medizinischen Hochschule Hannover habilitiert.

In this episode of Prescribing Lifestyle, Dr. Avi Charlton welcomes Dr. Sarah Hancock to discuss the significant issue of dental caries in New Zealand children and its impact on overall health. Dr. Hancock shares her research findings on the link between diet, particularly refined carbohydrates, and dental caries. She also provides practical advice for parents to help prevent dental caries and improve their children's health. Key Points Discussed: Dr. Sarah Hancock's Journey: Educational background in Physical Education and Health Technology Assessment. Personal experiences influencing her focus on diet and health. Start of her PhD in 2016, focusing on dental caries and diet in children. Dental Caries in New Zealand Children: High prevalence of dental caries leading to surgeries in young children. Connection between refined carbohydrate intake and dental caries. The impact of diet on overall health and chronic diseases. Practical Advice for Parents: Focus on progress, not perfection. Reduce snacking on ultra-processed foods. Encourage consumption of real foods like meat, cheese, and some fruits. Ensure adequate protein intake for children's growth and development. Avoid highly refined carb-based snacks. Future Directions: Dr. Hancock's training to become a health coach. Her goal to help families and children through practical dietary advice. Continued research on diet, dental health, and overall well-being. Dr Sarah's website https://drsarahhancock.com/about/ Exciting News: Announcement of the new e-book, Low-Carb Made Easy, now available. It includes the basic theory behind low-carb eating, a detailed food list, practical meal plans, and delicious recipes. Available at www.mlcclinic.com.au in the online store. Join the Low Carb Pro Community: https://avi-s-site.thinkific.com/bundles/low-carb-pro Engage in bi-weekly webinars and access extensive resources through Low Carb Pro. For $25 a month, join a supportive community dedicated to holistic health improvement. Website: Visit https://www.mlcclinic.com.au/ to learn more about our services and resources. Free Resources: Explore the free resources available on our website: https://mlcclinic.com.au/free-resources/ Social Media: Instagram: Follow me on Instagram https://www.instagram.com/dr_charlton_lifestyle_gp/ Facebook: Connect with me on Facebook at Dr Charlton Lifestyle GP YouTube: Subscribe to my YouTube channel: https://www.youtube.com/@avicharlton Free Facebook Community: https://www.facebook.com/groups/5714367278623084 Contact Me: Have questions or want to get in touch? Feel free to email me at avi.charlton@mlcclinic.com.au Note: Remember, this podcast is not a replacement for medical advice. Always consult with your healthcare provider for personalized medical treatment. Don't forget to subscribe, rate, and review the podcast on your favorite platform. Join our community on Facebook and download your free e-book from the https://www.mlcclinic.com.au

On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, the CEO of the Center for Innovation and Value Research, formerly known as the Innovation and Value Initiative (IVI). We discuss the strengths and limitations of health technology assessment (HTA), one major limitation being its lack of equity. We also touch on IVI's recent rebrand to the Center for Innovation and Value Research on July 16 and how people can get involved.

On this special episode of Tuesday Night IBS, we talk with the co-principal investigator, Alex Ford, MD, from Leeds University in the UK, about the ATLANTIS trial of Amitriptyline for irritable bowel syndrome (IBS) in primary care, which was funded by the Health Technology Assessment program of the National Institute for Health and Care Research and the TRITON trial using Ondansetron to manage irritable bowel syndrome with diarrhea.Dr. Alex Ford is a Professor and Honorary consultant gastroenterologist at St. James's University Hospital, Leeds, UK. His main interest is in the epidemiology, diagnosis, and treatment of disorders of gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia. He is an Associate Editor for Alimentary Pharmacology & Therapeutics. He has published over 450 peer-reviewed articles, including original scientific papers in The Lancet, JAMA, BMJ, Gastroenterology, Gut, Archives of Internal Medicine, and The American Journal of Gastroenterology.

On this special episode of Tuesday Night IBS, we talk with the co-principal investigator, Alex Ford, MD, from Leeds University in the UK, about the ATLANTIS trial of Amitriptyline for irritable bowel syndrome (IBS) in primary care, which was funded by the Health Technology Assessment program of the National Institute for Health and Care Research and the TRITON trial using Ondansetron to manage irritable bowel syndrome with diarrhea.Dr. Alex Ford is a Professor and Honorary consultant gastroenterologist at St. James's University Hospital, Leeds, UK. His main interest is in the epidemiology, diagnosis, and treatment of disorders of gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia. He is an Associate Editor for Alimentary Pharmacology & Therapeutics. He has published over 450 peer-reviewed articles, including original scientific papers in The Lancet, JAMA, BMJ, Gastroenterology, Gut, Archives of Internal Medicine, and The American Journal of Gastroenterology.

Is cannabis actually effective as a pain management tool or is it all just placebo? How does the media portrayal of cannabis research impact research? In part II of the cannabis series, we are joined by Dr. Filip Gedin, a postdoc in the Pain Neuroimaging Lab at Karolinska Institutet in Sweden. Dr. Gedin obtained his Ph.D. in health economics from Karolinska Institutet in 2020. In his PhD thesis, he explored the costs associated with back pain and the effectiveness of primary care interventions for individuals with persistent low back pain through systematic reviews, clinical trials, and register-based studies. He has previously worked at the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) as a health economist. SBU is tasked by the government with assessing healthcare and social service interventions via the use of systematic reviews. The focus of his postdoctoral research is to further understand how chronic pain develops through the PrePain project, along with continuing to evaluate treatments for pain. Dr. Filip Gedin's Lab Instagram: https://www.instagram.com/kipainandbrain/ Email: thinktwicepodcast@outlook.com Instagram: @thinktwice_podcast Patreon: https://www.patreon.com/ThinkTwicePodcast Disclaimer: Think Twice is a podcast for general information and entertainment purposes only. The content discussed in the episodes does not reflect the views of the podcast committee members or any institution they are affiliated with. The use of the information presented in this podcast is at the user's own risk and is not intended to replace professional healthcare services.

In this episode, Phil, Brett and Martin dicuss more sessions from ESCMID Global (Barcelona, 2024). We talk about sessions on cleaning the occupied bed space, SSI prevention and the difficulty of designing and executing good studies in IPC. We were particularly interested in papers from Italy on the use of probiotics in IPC and some papers from Prof Cassini's group are highlighted below. Calabro GE, Caselli E, Rognoni C, Laurenti P, Moscato U, ML DIP, et al. [Health Technology Assessment of the introduction of the Probiotic Cleaning Hygiene System (PCHS) in the Italian healthcare setting: update]. J Prev Med Hyg. 2023;64:E1-E35. https://www.ncbi.nlm.nih.gov/pubmed/37881619 D'Accolti M, Soffritti I, Bini F, Mazziga E, Cason C, Comar M, et al. Shaping the subway microbiome through probiotic-based sanitation during the COVID-19 emergency: a pre-post case-control study. Microbiome. 2023;11:64. https://www.ncbi.nlm.nih.gov/pubmed/36991513 D'Accolti M, Soffritti I, Bini F, Mazziga E, Mazzacane S, Caselli E. Pathogen Control in the Built Environment: A Probiotic-Based System as a Remedy for the Spread of Antibiotic Resistance. Microorganisms. 2022;10. https://www.ncbi.nlm.nih.gov/pubmed/35208679 Caselli E, Purificato I. Could we fight healthcare-associated infections and antimicrobial resistance with probiotic-based sanitation? Commentary. Ann Ist Super Sanita. 2020;56:263-6. https://www.ncbi.nlm.nih.gov/pubmed/32959791| Caselli E, D'Accolti M, Vandini A, Lanzoni L, Camerada MT, Coccagna M, et al. Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation. PLoS One. 2016;11:e0148857. https://www.ncbi.nlm.nih.gov/pubmed/26886448

In this episode, Phil, Brett and Martin dicuss more sessions from ESCMID Global (Barcelona, 2024). We talk about sessions on cleaning the occupied bed space, SSI prevention and the difficulty of designing and executing good studies in IPC. We were particularly interested in papers from Italy on the use of probiotics in IPC and some papers from Prof Cassini's group are highlighted below. Calabro GE, Caselli E, Rognoni C, Laurenti P, Moscato U, ML DIP, et al. [Health Technology Assessment of the introduction of the Probiotic Cleaning Hygiene System (PCHS) in the Italian healthcare setting: update]. J Prev Med Hyg. 2023;64:E1-E35. https://www.ncbi.nlm.nih.gov/pubmed/37881619 D'Accolti M, Soffritti I, Bini F, Mazziga E, Cason C, Comar M, et al. Shaping the subway microbiome through probiotic-based sanitation during the COVID-19 emergency: a pre-post case-control study. Microbiome. 2023;11:64. https://www.ncbi.nlm.nih.gov/pubmed/36991513 D'Accolti M, Soffritti I, Bini F, Mazziga E, Mazzacane S, Caselli E. Pathogen Control in the Built Environment: A Probiotic-Based System as a Remedy for the Spread of Antibiotic Resistance. Microorganisms. 2022;10. https://www.ncbi.nlm.nih.gov/pubmed/35208679 Caselli E, Purificato I. Could we fight healthcare-associated infections and antimicrobial resistance with probiotic-based sanitation? Commentary. Ann Ist Super Sanita. 2020;56:263-6. https://www.ncbi.nlm.nih.gov/pubmed/32959791| Caselli E, D'Accolti M, Vandini A, Lanzoni L, Camerada MT, Coccagna M, et al. Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation. PLoS One. 2016;11:e0148857. https://www.ncbi.nlm.nih.gov/pubmed/26886448

ROMA (ITALPRESS) - L'impatto economico e sociale delle Neoplasie linfoproliferative e l'importanza della gestione multidisciplinare del paziente. Questi i temi al centro del simposio promosso da BeiGene, azienda biotecnologica globale, dal titolo “Il burden economico della Macroglobulinemia di Waldenström e della Leucemia Linfatica Cronica e stima del potenziale impatto organizzativo legato alla gestione multidisciplinare dei pazienti”, organizzato in occasione della XVI edizione del Congresso Nazionale della Società Italiana di Health Technology Assessment. Una ricerca di ALTEMS è andata a indagare come l'approccio di un team multidisciplinare permetta di ottimizzare gli esiti dei pazienti e gli aspetti organizzativi ed economici.mgg/gsl

ROMA (ITALPRESS) - L'impatto economico e sociale delle Neoplasie linfoproliferative e l'importanza della gestione multidisciplinare del paziente. Questi i temi al centro del simposio promosso da BeiGene, azienda biotecnologica globale, dal titolo “Il burden economico della Macroglobulinemia di Waldenström e della Leucemia Linfatica Cronica e stima del potenziale impatto organizzativo legato alla gestione multidisciplinare dei pazienti”, organizzato in occasione della XVI edizione del Congresso Nazionale della Società Italiana di Health Technology Assessment. Una ricerca di ALTEMS è andata a indagare come l'approccio di un team multidisciplinare permetta di ottimizzare gli esiti dei pazienti e gli aspetti organizzativi ed economici.mgg/gsl

Listen By:Season 7Season 6Season 5Season 4Season 3Season 2Season 1Podcast Categories:Fertility and pregnancyGuest interviewsInfectious diseaseRespiratory healthSkincareSkincare for babiesMy somewhat political views!Listen By:Season 7Season 6Season 5Season 4Season 3Season 2Season 1Podcast Categories:Fertility and pregnancyGuest interviewsInfectious diseaseRespiratory healthSkincareSkincare for babiesMy somewhat political views!Listen By:Season 7Season 6Season 5Season 4Season 3Season 2Season 1Season 7Season 6Season 5Season 4Season 3Season 2Season 1Podcast CategoriesGuest interviewsFertility and pregnancyInfectious diseaseRespiratory healthSkincareSkincare for babiesMy somewhat political views!John Test PageGuest interviewsFertility and pregnancyInfectious diseaseRespiratory healthSkincareSkincare for babiesMy somewhat political views!John Test PageA WonderCare PodcastChicken Pox Vacccination and the Childhood Immunisation ProgrammePlay EpisodePause EpisodeMute/Unmute EpisodeRewind 10 Seconds1xFast Forward 30 seconds00:00/00:21:40SubscribeShareAmazonApple PodcastsGoogle PodcastsSpotifyRSS FeedShareLinkEmbedDownload file | Play in new window | Duration: 00:21:40 | Recorded on 22/07/2023Subscribe: Amazon | Apple Podcasts | Google Podcasts | Spotify Amazon Apple Podcasts Google Podcasts Spotify Chickenpox Vaccination and the Childhood Immunisation ScheduleRelated Episodes: DR NIAMH LYNCH ON THE NEUROLOGICAL COMPLICATIONS OF CHILDHOOD ILLNESSES.CHICKEN POX  – TREATMENT AND CARE.Is the chickenpox vaccine going to be available in Ireland?In this episode I discuss the recent Health Technology Assessment conducted by the HIQA which explored if the chickenpox vaccine should be included in the childhood vaccination schedule.I answer all of the questions that came through my question box over on my Instagram account @WonderCare_IrlSeason 5 Partnership – Salin Plus (available here!)I am so thrilled to be partnering with Salin plus for an entire Season packed with lots of family health information! This 100% natural salt therapy device is suitable for both adults and children!  Tune in to learn more!Support this Podcast Simply following and reviewing this podcast can make a huge difference! I would be so grateful if you could follow or subscribe to the show! I aim to support parents and appreciate every one of you who take the time from your day to learn something new along with me!  I explain medical conditions and their treatment as well as chatting with experts about a whole range of medical and parenting challenges. Of course I can't forget our little voices episodes where I chat with kids and hear things from their point of view!  I'm also extremely grateful to everyone who contributes to a real lives episode – I learn so much from these and am privileged to be able to share your story which will help people who find them in a similar situation in life. You can check out all of my previous episodes by clicking right here!Calamine Lotion 100ml€5.45Add to basketPoxClin CoolMousse 100ml€20.55Add to basketSale!Salin Plus Air Purifier (Salt Therapy) – Respiratory Health€117.45 €160.00Add to basket Hosted on Acast. See acast.com/privacy for more information.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Beyond Cost-Effectiveness: Insights for Effective Altruism from Health Economics, published by TomDrake on June 1, 2023 on The Effective Altruism Forum. Hi Everyone - partly inspired by attending the recent EA Global London conference a couple of weeks ago, I've written a CGD Blog with some thoughts on EA's approach to prioritisation and methods in health economics (specifically Health Technology Assessment). This is a link post and as CGD staff I have to post on our platform, but since the key target audience is EAs, I'd be delighted to hear thoughts from this community. I'll be sure to monitor the comments section and perhaps the discussion will feed into future work. The differences between EA and health econ I highlight include:1. Approaches generalising cost-effectiveness evidence 2. Going beyond cost-effectiveness in determining value3. Deliberative appraisal4. Institutionalisation of a participatory process Please click through for the full blog. Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

https://www.drstevenlin.com/low-carb-diet-plan-weight-loss/There is a growing amount of evidence for the benefits of a low-carb diet for weight loss. If you're wondering if this diet choice might be for you, there's an interesting connection between the risk of dental decay and losing weight.Sugar and simple carbohydrates are known to increase the risk of cavities. Low-carbohydrate diets can reduce the risk of cavities through this mechanism, so can it also improve your metabolism to reduce unwanted body fat? Through the understanding of the mouth-gut connection, we can see that reducing our sugar consumption, as well as simple carbohydrates on lower carbohydrate diets may be effective to improve overall health.To discuss this topic is Dr. Sarah Hancock her PhD thesis on the benefits of low-carb diets at Auckland University in Public health and nutrition. She holds two degrees in Physical Education with Honours and Health Technology Assessment. In this discussion, we explore the evidence base for low-carb diets for both weight loss and better dental health.

Dr Máirín Ryan, HIQA's Deputy CEO and Director of Health Technology Assessment

If you're a statistician working in a regulatory setting, you're probably familiar with estimands as a way to frame the clinical question of interest. But what's the role of estimands beyond regulatory approval, in a Health Technology Assessment setting? That question is especially important these days where the framework for pan-European HTA is taking shape. In this episode, we'll touch on some HTA body views around estimands, and reflect on how current draft guidelines for EU HTA do and don't address estimands.

Dr Máirín Ryan, HIQA's Deputy CEO and Director of Health Technology Assessment speaks to us

Author, doctor and college professor John Abramson joins Tim to talk about his book called, “Sickening: How Big Pharma Broke American Health Care and How We can Repair It.” John has been on the faculty of Harvard Medical School for over 25 years, and prior to that spent many years in private practice. In this episode, John about America's healthcare system, which often traces its roots to how drugs are approved for use and marketed to both doctors and consumers. https://traffic.libsyn.com/secure/shapingopinion/John_Abramson_Sickening_auphonic.mp3 Prior to the pandemic, most Americans knew much less, or even cared about how drugs were approved. Vaccines, drugs, medicines and other medical treatments are approved by the Food and Drug Administration, the FDA.  Before the pandemic, most Americans assumed that the FDA and the federal government had their best interests at heart, and that anything approved by the FDA was good for them. When TV viewers watched ads for pharmaceuticals, they assumed that these new drugs had to pass the test of innovation, of efficacy, and that in the end, the new drugs were improvements over the old drugs. The pandemic changed all of that for some, not because of lost trust in the mission of the FDA or other regulatory bodies. And not because of lack of faith in the ability for pharmaceutical companies to provide lifesaving and health-improving treatments. Or their ability to be innovative. What has happened is that America has gotten a peak behind the curtain, and it's not sure it likes what it sees. That's exactly what our guest in this episode has spent much of his life doing. John Abramson is a medical doctor. He's a former expert witness in numerous legal proceedings over the questionable practices of some pharmaceutical companies or executives. Like so many, he entered the medical profession to help people get better or stay healthy. Then he got his own glimpse behind the curtain. Links Sickening: How Big Pharma Broke American Health Care and How We Can Repair It, by John Abramson (Harper Collins' website) Overdo$ed America, by John Abramson (Harper Collins' website) Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis, New England Journal of Medicine (November 23, 2000) Risk of cardiovascular events associated with selective COX-2 inhibitors, Journal of the American Medical Association (August 2001) Vioxx Lawsuits, Drugwatch.com Health Technology Assessment, PubMed.gov E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage, Wall Street Journal (November 1, 2004) Withheld Study on Vioxx Published This Week in Lancet, Kaiser Health News (June 11, 2009) Diabetes Prevention Program New England Journal Of Medicine 2002, DiabetesTalk.net About this Episode's Guest John Abramson John Abramson MD, MS, has served as a family physician for 22 years. He was twice voted “best doctor” in his area by readers of the local newspapers and three times selected by his peers as one of a handful of best family practitioners in Massachusetts. He has been on the faculty at Harvard Medical School for 16 years, where he has taught primary care and currently teaches health care policy. He currently consults as an expert in litigation involving the pharmaceutical industry and has served as an unpaid consultant to the FBI and Department of Justice. Dr. Abramson has appeared on more than 65 national television shows, including two appearances on the Today Show, and more recently on the Dr. Oz Show. He was written op-ed pieces in the New York Times LA Times and others. In addition to his book, Sickening, He is the author of the national best-selling book Overdo$ed America.

In this episode, Sujani sits down with Ted Witek Jr., the director of the DrPH program at Dalla Lana. They discuss Ted's diverse career journey, his research work, and Canada's first DrPH program.You'll LearnTed's career from pharmaceutics to directing the DrPH at Dalla LanaTed's research interests and achievementsHow building relationships is important in your careerThe value of seizing opportunities and keeping an open mindWhat Ted has learned in his position from directing the DrPH programA brief summary about Dalla Lana's DrPH programWhat's next for the DrPH programToday's GuestDr. Witek served Boehringer Ingelheim Pharmaceuticals for nearly 25 years where he held various pharmacology and clinical research positions, including Director of Respiratory and Immunology Clinical Research leading to his roles as President and CEO of Boehringer Ingelheim's Canadian and Portuguese operations. He led the Global Operating Team for Spiriva serving as Co-Chair of the Global Alliance with Pfizer.Dr. Witek also was Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva (Formerly Theravance, Inc.). He also served on the Board of Directors of Canada's Research-Based Pharmaceutical Companies (Rx&D) including Chair of the Health Technology Assessment and Public Relations Committee. He was appointed to the Ontario Health Innovation Council and advisor to the Design for Health Program at OCAD University. He is currently  an Adjunct Professor & Senior Fellow at the University of Toronto's School of Public Health & Leslie Dan Faculty of Pharmacy. He serves as Director of the DrPH program. Dr. Witek is the author of more than 100 scientific papers as well as several chapters and books.Dr. Witek holds a Doctor of Public Health from Columbia University and a Master of Public Health from Yale University and an MBA from Henley Management College in the UK.ResourcesConnect with Ted on LinkedInFollow Ted on Twitter Learn more about Ted Learn more about Dalla Lana's DrPH programListen to the previous episode about the DrPH program with Erica Di RuggieroOther PH SPOT resources:Share ideas for the podcast: Fill out this formNever heard of a podcast before? Read this guide we put together to help you get set up.Be notified when new episodes come out, and receive hand-picked public health opportunities every week by joining the PH SPOT community.Contribute to the public health career blog: www.phspot.ca/contributeUpcoming course on infographics: phspot.ca/infographicsLearn more about The Public Health Career ClubSupport the show

Dass Musik gut für das seelische Wohlbefinden ist, das ist nicht neu. Eine Studie des Austrian Institute for Health Technology Assessment hat jetzt gezeigt: Musiktherapie kann sich positiv auf durch die Pandemie ausgelöste psychische Probleme auswirken. Was genau Musiktherapie ist und wie sie eingesetzt wird, damit hat sich unsere Kölncampus-Reporterin Marie Schwab einmal genauer befasst.

Seit 2017 prüft das Bundesamt für Gesundheit (BAG) medizinische Versorgung mittels dem Health Technology Assessment – dem HTA-Prüfverfahren. So sollen Kosten von jährlich über 200 Millionen Franken gespart werden. Eine Zwischenbilanz zeigt: Die Resultate liegen deutlich hinter den Erwartungen. Weitere Themen: In zwei Wochen treffen sich in Lugano Vertreter dutzender Länder, um über den Wiederaufbau der Ukraine zu sprechen. Doch macht dies überhaupt Sinn, so lange der Krieg noch im Gang ist? Bundespräsident Ignazio Cassis hat vor den Medien Stellung genommen. In den letzten Tagen ist deutlich weniger Gas von Russland nach Europa geflossen. Als Grund gibt der russische Staatskonzern Gazprom an, sogenannte Verdichterturbinen seien in Revision. Viele Länder fürchten deshalb um ihre Versorgungssicherheit. Deutschland und Österreich wollen sogar wieder vermehrt auf Kohlekraft setzen.

SOUNDS OF SCIENCE - EPISODE 6 The Cross-Border Healthcare Directive (Directive 2011/24/EU) marked a milestone for European patients. It created a legal framework for the patient's right to seek healthcare in another Member State and to be reimbursed. It also provided a legal basis for enhanced European cooperation in key areas of healthcare – including quality and safety, Health Technology Assessment and eHealth, and rare diseases. On May 12, the Commission published their long awaited evaluation of the Cross-Border Healthcare Directive. The report outlines several areas for improvement, but does not call for a reopening of the Directive, which would be a political decision as well. As more Advanced Therapy Medicinal Products (ATMPs) have become available across Member States, it is still unclear how the cross-border healthcare framework will make access to such transformative treatment abroad more accessible. In this podcast, we're addressing a number of complex issues with a lot of terminology so today we'll be discussing the CBH in a holistic manner. The speakers will be able to clarify between the concept of CBH and the Directive itself. Joining us on this podcast are: Thomas Bols, Head of Government Affairs and Patient Engagement, PTC Therapeutics Victor Maertens, Government Affairs Manager, EUCOPE ------------------------------------------------------ The European Alliance for Transformative Therapies (TRANSFORM) is a multi-stakeholder Alliance that connects Members of the European Parliament (MEPs) and policy-makers with patient groups, medical experts and associations, scientists, researchers, industry actors, networks and other relevant stakeholders. More info at https://transformalliance.eu/ EUCOPE's Position Paper - Cross Border Healthcare for Patients: What can be done? Learn more about EUCOPE at www.eucope.org

Welcome to episode 4, discussing the architectural developments in EHDEN, within Work Package 4, co-led by Julia Kurps, Team Lead of the Real World Data Team, The Hyve, and Michel Van Speybroeck, Director, Data Sciences, Janssen. We explore the considerable opportunity, challenges and innovation required to develop a central Portal for EHDEN than can support research and collaboration between Data Partners and researchers. Julia and Michel discuss their own unique backgrounds and careers, and then we investigate the work they are co-leading with WP4 colleagues across diverse public and private organisations to build the EHDEN Portal, central to both the sustainability and the use of EHDEN in conducting open science research using OMOP-mapped data at scale for network studies. In the main body of the discussion, Julia and Michel outline what EHDEN is working to achieve with the Portal build, encompassing discoverability via a Catalogue through to standardised analytics (in collaboration with OHDSI) and an Evidence Hub. Furthermore, EHDEN is extending the OHDSI analytical tools, as well as supporting methodological aspects within an integrated framework, while incorporating processes, procedures and governance. Overall, this is within a wider ecosystem of Data Partners and researchers, inclusive of the Portal, but also training support via, e.g., the EHDEN Academy. Innovation, described in the discussion, has to be sustainable, inclusive of a wider and growing community of those who can conduct open science research themselves, with diverse use cases, such as in Health Technology Assessment, Pharmaceuticals, or with Data Partners, all who have specific expectations, requiring a balance within a technical architecture. The views expressed by the participants are personal and not necessarily reflective of their organisations.

There are more than 110,000 naturopath and naturopathic doctors globally. The naturopathic profession has existed as a distinct healthcare system for over a hundred years and is practiced in over a hundred countries. It has produced over 2000 peered reviewed articles since 1987. 51 naturopathic doctors from 11 countries across 5 world regions have contributed to the chapters of this Health Technology Assessment for Naturopathy.As Dr Amie Steel shares, “If you want to know what we are, what we do, why we do it, what the evidence is, everything else, how might I be able to use this? how we're regulated, everything you want to know, it's all in this book.”     

In this first episode of season 2 we discuss Health Technology Assessment, a multidisciplinary, transparent process for evaluating therapeutic agents and technologies in terms of efficacy and value in treating the indicated population, within the wider context of a country's healthcare system. Joining us to discuss this is Dalia Dawoud, Senior Scientific Advisor at NICE, the National Institute for for Health and Care Excellence in London, and Eline van Overbeeke, Health Economics and Outcomes Research Manager, Pfizer, both co-leading work package 2 in EHDEN focusing on evidence generation in HTA and outcomes benchmarking. In a broad ranging conversation Dalia and Eline, viewing this from a HTA agency and a biopharmaceutical company, cover what is 'HTA', and how RWD is rapidly growing as a data source for evidence generation to support contextual insights into therapeutic areas, longer term evaluation in-market, especially also where RCT data is minimal or absent, and in validation of modelling and assumptions. Challenges in utilising RWD are discussed, and how EHDEN is responding to this, for instance as addressed in the PharmacoEconomics paper of late 2019. Finally, we focus on the learning curve for all concerned and a forthcoming, initial module of courses related to HTA and use of RWD/RWE to be launched in the EHDEN Academy. The views expressed by the participants are personal and not necessarily reflective of their organisations.

Calls for more involvement from the United States government in how medicines are priced have inevitably given rise to questions about the infrastructure required to adjudicate questions of value in medicine.   One possibility would be the establishment of a health technology assessment body -- common elsewhere in the world but historically viewed skeptically in the United States -- and Lou Garrison from the CHOICE Institute at the University of Washington spoke with us about the philosophical basis and practical realites of a U.S. HTA.  

O entrevistado desta semana no Empreendedor 10 é o Bráulio Bonoto, empreendedor brasileiro radicado em Santiago, no Chile. Ele é Diretor Executivo da Psicologia Viva na América Latina, empresa brasileira com foco em ajudar as pessoas a alcançarem melhor equilíbrio mental e empresas com funcionários mais produtivos. Bráulio é Mestre em Saúde Pública (Health Technology Assessment) com foco em telessaúde, e tem experiência europeia em saúde. É empreendedor digital desde 2012 e cofundador de três startups. Foi acelerado por dois programas de Startup (SEED-MG e Startup Chile). Não perca de segunda à sexta, às 10 horas, com reprise às 22 horas, na www.rocktronic.com.br!

O entrevistado desta semana no Empreendedor 10 é o Bráulio Bonoto, empreendedor brasileiro radicado em Santiago, no Chile. Ele é Diretor Executivo da Psicologia Viva na América Latina, empresa brasileira com foco em ajudar as pessoas a alcançarem melhor equilíbrio mental e empresas com funcionários mais produtivos. Bráulio é Mestre em Saúde Pública (Health Technology Assessment) com foco em telessaúde, e tem experiência europeia em saúde. É empreendedor digital desde 2012 e cofundador de três startups. Foi acelerado por dois programas de Startup (SEED-MG e Startup Chile). Não perca de segunda à sexta, às 10 horas, com reprise às 22 horas, na www.rocktronic.com.br!

O entrevistado desta semana no Empreendedor 10 é o Bráulio Bonoto, empreendedor brasileiro radicado em Santiago, no Chile. Ele é Diretor Executivo da Psicologia Viva na América Latina, empresa brasileira com foco em ajudar as pessoas a alcançarem melhor equilíbrio mental e empresas com funcionários mais produtivos. Bráulio é Mestre em Saúde Pública (Health Technology Assessment) com foco em telessaúde, e tem experiência europeia em saúde. É empreendedor digital desde 2012 e cofundador de três startups. Foi acelerado por dois programas de Startup (SEED-MG e Startup Chile). Não perca de segunda à sexta, às 10 horas, com reprise às 22 horas, na www.rocktronic.com.br!

O entrevistado desta semana no Empreendedor 10 é o Bráulio Bonoto, empreendedor brasileiro radicado em Santiago, no Chile. Ele é Diretor Executivo da Psicologia Viva na América Latina, empresa brasileira com foco em ajudar as pessoas a alcançarem melhor equilíbrio mental e empresas com funcionários mais produtivos. Bráulio é Mestre em Saúde Pública (Health Technology Assessment) com foco em telessaúde, e tem experiência europeia em saúde. É empreendedor digital desde 2012 e cofundador de três startups. Foi acelerado por dois programas de Startup (SEED-MG e Startup Chile). Não perca de segunda à sexta, às 10 horas, com reprise às 22 horas, na www.rocktronic.com.br!

O entrevistado desta semana no Empreendedor 10 é o Bráulio Bonoto, empreendedor brasileiro radicado em Santiago, no Chile. Ele é Diretor Executivo da Psicologia Viva na América Latina, empresa brasileira com foco em ajudar as pessoas a alcançarem melhor equilíbrio mental e empresas com funcionários mais produtivos. Bráulio é Mestre em Saúde Pública (Health Technology Assessment) com foco em telessaúde, e tem experiência europeia em saúde. É empreendedor digital desde 2012 e cofundador de três startups. Foi acelerado por dois programas de Startup (SEED-MG e Startup Chile). Não perca de segunda à sexta, às 10 horas, com reprise às 22 horas, na www.rocktronic.com.br!

This episode of Healthy Cities in the SDG Era takes a different approach in thinking about the Sustainable Development Goals, by zooming out from a focus on specific SDGs, to talking about global health diplomacy, a process which is linked to many of the Goals.Professor Ilona Kickbusch is the founder and chair of the Global Health Centre of the Graduate Institute of International and Development Studies, Geneva. Previously, she served as the head of the global health division of Yale University and held various positions at the World Health Organization. In 2016, Prof. Kickbusch was awarded the Cross of the Order of Merit of the Federal Republic of Germany in recognition of her significant contributions to shaping the field of global health with her practical and theoretical expertise. Currently, she is undertaking responsibilities in several distinguished boards and commissions such as the Lancet FT Commission Governing Health Futures – Growing up in a digital world, UHC 2030 and Global Preparedness Monitoring Board.Dr. Srikanth Kondreddy is an Investigator at the Bruyère Research Institute, University of Ottawa, and a Senior Fellow at the WHO Collaborating Centre for Knowledge Translation and Health Technology Assessment in Health Equity, Ottawa. He also works with UN agencies and he contributes to Think 20 (T20), a policy engagement group of the G20, and has contributed to projects such as the T20 Task Force on "COVID-19 - Multidisciplinary Approaches to Complex Problems". He has research and teaching interests in global health policy, governance, and diplomacy. He is currently researching on global health governance, pandemic preparedness and response, global health security, international health regulations, and international cooperation in health.CREDITS: This podcast is co-hosted by Dr. Erica Di Ruggiero, Director of the Centre for Global Health, and Ophelia Michaelides, Manager of the Centre for Global Health, at the Dalla Lana School of Public Health, University of Toronto, and produced by Elizabeth Loftus. Audio editing is by Anwaar Baobeid. Music is produced by Julien Fortier and Patrick May. It is made with the support of the School of Cities at the University of Toronto. 

Intervista a Marco Marchetti, Direttore Centro Nazionale per l’Health Technology Assessment, Istituto Superiore di Sanità.L’utilizzo dei real world data e delle informazioni in essi contenute può portare a un nuovo paradigma nel processo di valutazione di farmaci e dispositivi medici. Fondamentale il ricorso a sistemi di digitalizzazione spinta sia nell’imputazione dei dati che nel processo di analisi ed estrazione.

LEARNING OUTCOMES1. Explore the relationship between gut microbial ecology and fibromyalgia – specifically the links between SIBO and Helicobacter pylori infections and the aetiology of this chronic disease.2. Review evidence linking the microbiome to chronic pain disorders and central sensitisation syndromes, including its role in promoting production of neuropeptide Y and substance P.3. Examine the underlying links between fibromyalgia, chronic fatigue syndrome (CFS), and irritable bowel syndrome (IBS).Sharon Erdrich is a clinical naturopath and nutritionist based in Auckland, New Zealand. Sharon has more than 40 years' experience in the health sector and runs a busy practice where she specialises in digestive disorders. Sharon started her working life as a nurse, gaining her nursing registration in 1980 and working primarily in intensive care settings for 20 years. In 2000 Sharon then returned to study, gaining qualifications in herbal medicine, naturopathy, massage, and aromatherapy. While practicing, Sharon also enrolled in a Masters in Human Nutrition at the University of Auckland. For her Master's thesis at the University of Auckland, Sharon investigated the degree of DNA damage in men with prostate cancer before and after a 3-month Mediterranean-style diet. She is currently a PhD researcher at the University of Sydney; her PhD project is examining relationships between the oral and gastrointestinal microbiome in people living with fibromyalgia. Sharon has established a hydrogen-methane breath testing facility in Auckland – the only one of its kind in New Zealand. She is also contributing to the development of the Health Technology Assessment to support the World Naturopathic Federation's application to the World Health Organisation.

This is a special edition of the NICE Talks podcast to celebrate the inaugural World Evidence-Based Healthcare (EBHC) Day on Tuesday 20 October 2020. NICE is an official partner for World EBHC Day and the theme of this year's event is ‘from evidence to impact'. Dr Adriana Robayo from the Colombia Instituto de Evaluacion de Tecnologias en Salud (Institute of Health Technology Assessment) joins our host – NICE International's Pilar Pinilla-Dominguez – to discuss the challenges in adopting an evidence-based approach to improving health outcomes. To find out more about World Evidence-Based Healthcare Day visit https://worldebhcday.org/

In this month's episode, Shae speaks with mother and son duo Lois and Nicholas Letchford. Lois Letchford's dyslexia came to light at the age of 39, when she faced teaching her seven-year-old non-reading son, Nicholas. Examining her reading failure caused her to adapt and change lessons for him. The results were dramatic. Lois subsequently qualified as a reading specialist, using her non-traditional background, multi-continental experience, and her passion for assisting other failing students. Her learning equips her with a unique skill set and perspective. The goal is always to create active readers, thus engaging students in the joy of reading and learning. Lois continuously engages in reading academic literature, strengthening the connection between research and teaching practice. Although living with dyslexia, Lois overcomes writing challenges-daily. She writes for her students and writes blogs for parents and teachers. Reversed: A Memoir is her first book. Here, she details the journey of her son's dramatic failure. She has become a sort-after speaker, sharing creative, engaging insights with humour and grace. Lois speaks on numerous podcasts and reading conferences around the world. Dr. Nicholas Letchford is a consultant in the international development sector in the UK and a fellow dyslexic. He gained his DPhil (PhD) in Mathematics at the University of Oxford, where he modelled the process of cavitation in engine lubricant films, funded by BP. Nicholas has a broad skill set spanning mathematics, statistics, health economics, and engineering, with a sustained interest in public health, health economics, and policy evaluations. He holds dual undergraduate Hons degrees in Mathematics and Mechanical Engineering from the University of Tasmania, and an MSc in Health Technology Assessment from the University of Glasgow.   This is an inspirational podcast that talks about one mother's love for her son and everything she did to help him to read and go on to become a Doctor at Oxford Univerity.    

Leela Barham is a Health Economist by training with an MSc Health Economics from the University of York and BSc Economics from the University of Nottingham. Leela has over a decade of experience in consulting, working with clients from across the world. Leela focuses on policy and health economic issues from pharmaceutical pricing to Health Technology Assessment and more. Leela has worked with patient organizations, the NHS, a health insurer, think tanks, the pharmaceutical industry, and the medical device industry and has been an expert reviewer for the Department of Health to support on issues on innovation. Leela has also worked for the Royal College of Nursing and NERA Economic Consulting, and has been a member of the Department of Health's External Advisory Group on Payment by Results and the HFMAs Costing Special Interest Group. Leela's work has been published in a number of journals and she also regularly contributes to pharmaceutical industry magazines. She has also been a peer reviewer for journals including the European Journal of Health Economics and The Patient. 00:00 What a Value Framework looks like. 02:00 Identifying the components of value. 04:00 Giving Clinicians the tools to have conversations about value. 07:00 Accepting and Understanding uncertainty. 07:50 “Here are some gaps, how can we work collectively to explore that?” 08:20 “It's not about finding trying to find an average patient, it's about saying, here's a collection of options.” 10:00 Patient Centricity. 12:00 “How can we make sure the value framework is not a rulebook?” 14:15 The opportunity of Value Frameworks. 15:00 Consumer reports in Healthcare. 17:00 Comparative clinical effectiveness, incremental cost effectiveness, and contextual considerations in Value Frameworks. 17:45 Issues of budget impact. 19:40 “It's not just the report that comes out, but the conversations that come out of that.” 22:20 What a Value Framework looks like at the Clinical Level. 25:00 “These are guidelines, not timelines.” 26:20 “Can we derive systems that incentivize behaviors?” 26:30 Putting Value-Based pricing alongside Value-Based contracting. 30:00 Value Frameworks in end-of-life care. 34:00 You can learn more on Leela Barham's Facebook and her blog.

In this week's podcast Andrew Farmer from the National Institute of Health Research, Health Technology Assessment programme (NIHR HTA), tackles uncertainty. Also, Andrew Clark from the University of Hull tells us that the case for administering oxygen isn't air tight.

Guest: Winifred Hayes, PhD Host: Bruce Japsen The health technology assessment, something gaining momentum in hospitals as a way to improve patient care, can be a challenge to implement. Dr. Winifred Hayes, founder and chief executive officer of Hayes Inc. tells host Bruce Japsen how this can be done and what the doctor's role should be in this process.